Enanta Pharmaceuticals Inc (ENTA)

[willyw]

These are only called "high dose or low dose"

We don't know if they are higher off of the baseline or lower than what was guessed. They are only higher or lower in respect to themselves. I rather doubt that they are higher by a large degree.

I don't have an answer to the question which seems to be if the drugs seem to require different dosings for different genotypes.

I think it a false ideal 1; pill for all genotypes.

What we need are low cost effective cures, available sooner.
The number of pills or the ability to treat all with one pill may be the goal of a drug company, but if you are dying of G-3, you don't care if the cure happens to be different than other genotypes.
You care that they develop a cure for YOUR genotype.

Maybe Abbvie's thinking will be the same as Gilead's, maybe different.

In 6-7 weeks the data will be out and we will have a better handle on what is going on, but questions get answered, and give rise to newer ones. :)

Anyway....possibly in answer to the question, if to cure genotype 3 requires 2 or 3 drugs, or 2 DAA's and RBV, the size of the dose may play into whether 1 or 2 pills are needed, co-formulation, and such, or optimizing things; a mild tweak for extra safety or efficacy.

Remember the 1000/ pill?
Same thing may go for dosing. Instead of 100/mg, what if only 88 1/3 is the sweet spot?

In other words, I have no idea. : )